STOCK TITAN
  1. Home
  2. News
  3. NVCR

NovoCure Limited - $NVCR STOCK NEWS

Welcome to our dedicated page for NovoCure news (Ticker: $NVCR), a resource for investors and traders seeking the latest updates and insights on NovoCure stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NovoCure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NovoCure's position in the market.

News

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Rhea-AI Summary
Novocure (NVCR) announced that the FDA has accepted its PMA application for the use of TTFields therapy in treating non-small cell lung cancer (NSCLC) after platinum-based therapy. The filing date was December 15, 2023, and the company expects a regulatory decision in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.75%
Tags
clinical trial
-
News

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Rhea-AI Summary
Novocure (NVCR) completes enrollment in TRIDENT trial, evaluating Optune Gio for newly diagnosed glioblastoma patients. Final data expected in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
clinical trial
-
News

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Rhea-AI Summary
Novocure (NVCR) reports preliminary full year 2023 net revenues of $509 million, 4% increase in Q4 net revenues, and submission of PMA application for TTFields in NSCLC to FDA. The company also appointed a new Chief Medical Officer and will present at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
earnings
News

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Rhea-AI Summary
Novocure (NVCR) appoints Dr. Nicolas Leupin as Chief Medical Officer, bringing extensive experience in biotechnology and pharmaceutical industries. Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as Novocure advances its clinical pipeline and prepares to treat an expanded patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
management
-
News

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Novocure (NVCR) to participate in 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.2%
Tags
conferences
-
News

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Rhea-AI Summary
Novocure (NVCR) announces strategic restructuring to prioritize metastatic non-small cell lung cancer launch and reduce residual operating expenses by approximately $60 million. The plan includes a reduction in headcount of approximately 200 colleagues, 13% of total workforce.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
News

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
Novocure (NVCR) executives William Doyle and Ashley Cordova will participate in the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023. The company will host a fireside chat and one-on-one meetings with investors. Live webcasts will be available on the Investor Relations page of Novocure’s website, with replays accessible for at least 14 days. Novocure uses its Investor Relations website to disclose material non-public information and comply with Regulation FD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
News

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Rhea-AI Summary
Novocure (NVCR) to Present New Data on TTFields Therapy at 2023 SNO Annual Meeting in Vancouver
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
clinical trial
-
News

Novocure Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Novocure reports quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.53%
Tags
earnings
News

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Rhea-AI Summary
Novocure announces participation in ESMO Congress 2023 and presents new analysis on Tumor Treating Fields therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
none
Stock NVCR logo
NovoCure Limited

Nasdaq:NVCR

NVCR Rankings

#1780 Ranked by Market Cap
#5351 Ranked by Stock Gains
N/A Ranked by Dividends

NVCR Stock Data

2.37B
95.92M
1.67%
85.87%
4.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ST. HELIER

About NVCR

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.